Intelligence · Patents
Patents expiring in 2029
Annual patent cliff calendar for 2029 — US pharmaceutical patents by expiration date.
- Patents
- 675
Quick answer
675 indexed pharmaceutical patents have expiration dates in 2029. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 7550595
Biphenyl compounds useful as muscarinic receptor antagonists
granted -
US 7550275
Expression, purification and uses of a Plasmodium falciparum liver stage antigen 1 polypeptide
granted -
US 7550460
2,4-pyrimidinediamine compounds and their uses
granted -
US 7550587
Photosensitizer and method for production thereof
granted -
US 7550454
Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
granted -
US 7550459
Tetrahydroquinoline analogues as muscarinic agonists
granted -
US 7550141
Methods for imaging tumor vasculature using conjugates that bind to aminophospholipids
granted -
US 7550005
Coated implantable medical device
granted -
US 7550590
Dipeptidyl peptidase inhibitors
granted -
US 7550598
Kinase inhibitors
granted -
US 7553962
Cross-linked glycopeptide-cephalosporin antibiotics
granted -
US 7553484
Modulating neuronal outgrowth via the major histocompatibility complex class I (MHC I) molecule
granted -
US 7553840
4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
granted -
US 7553490
Vaccines against Escherichia coli O157 infection
granted -
US 7554021
Composition and method for self-assembly and mineralization of peptide amphiphiles
granted -
US 7553971
Aryl aniline β2 adrenergic receptor agonists
granted -
US 7553931
Complement depletion using recombinant human C3-derivatives
granted -
US 7553867
Furan or thiophene derivative and medicinal use thereof
granted -
US 7553855
Compositions of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
granted -
US 7553935
Modified vitamin K-dependent polypeptides
granted -
US 7553934
Modified vitamin K-dependent polypeptides
granted -
US 7553653
Variants and chemically-modified variants of phenylalanine ammonia-lyase
granted -
US 7553852
Caspase inhibitors and uses thereof
granted -
US 7553936
Anti-TREM-like transcript-1 (TLT-1) antibodies and compositions
granted -
US 7557194
Antibody materials for an IBD-associated polypeptide
granted -
US 7557096
Synthesis of combretastatin A-4 prodrugs and trans-isomers thereof
granted -
US 7556942
Tumor suppressor designated Hippo
granted -
US 7556927
Methods for diagnosing, imaging and treating atherosclerotic disease
granted -
US 7557251
Production of gossypol co-crystals
granted -
US 7557212
Tricyclic derivatives as LTD4 antagonists
granted -
US 7557247
Crystalline form of β2 adrenergic receptor agonist
granted -
US 7557196
hGC-1, a gene encoding a member of the olfactomedin-related protein family
granted -
US 7557207
Spiro 2,4-pyrimidinediamine compounds and their uses
granted -
US 7557106
Substituted pyrimidines useful as protein kinase inhibitors
granted -
US 7557126
Diphenylmethyl compounds useful as muscarinic receptor antagonists
granted -
US 7557084
IL-18 specific polypeptides and therapeutic uses thereof
granted -
US 7556926
Methods for screening insulin-sensitizing agents
granted -
US 7556804
Anti-HGF-R antibodies and their use
granted -
US 7557138
5-phenoxyalkoxypsoralens and methods for selective inhibition of the voltage gated Kv1.3 potassium channel
granted -
US 7557210
2,4-pyrimidinediamine compounds and their uses
granted -
US 7557081
Alpha-1-acid glycoprotein for the treatment of diabetes
granted -
US 7560471
Indolylpiperidine derivatives as potent antihistaminic and antiallergic agents
granted -
US 7560469
Biphenyl compounds useful as muscarinic receptor antagonists
granted -
US 7560466
Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
granted -
US 7560440
Regulation of angiogenesis with zinc finger proteins
granted -
US 7560437
Nucleic acid compositions for eliciting an immune response against telomerase reverse transcriptase
granted -
US 7560265
Compositions for regulation of tumor necrosis factor-alpha
granted -
US 7560229
Methods of use of the enzymes of mycothiol synthesis
granted
Frequently asked questions
How many pharma patents expire in 2029?
675 published patents in our USPTO index have expiration dates falling in calendar year 2029.